News Column

Boston Scientific Announces Results For Second Quarter Ended June 30, 2014

August 4, 2014

By a News Reporter-Staff News Editor at Biotech Business Week -- Boston Scientific Corporation (NYSE: BSX) generated sales of $1.873 billion during the second quarter ended June 30, 2014, compared to the company's guidance range for the quarter of $1.840 to $1.890 billion. This represents 4 percent operational revenue growth (constant currency basis, excluding divested businesses) and 4 percent revenue growth on a reported basis, all compared to the prior year period. The company achieved adjusted earnings per share of $0.21 for the period, compared to $0.18 a year ago, and GAAP earnings of $4 million, or approximately $0.00 per share, compared to $0.10 a year ago (see also Biotechnology Companies).

"We had a strong second quarter, delivering balanced growth across our divisions," stated Mike Mahoney, president and chief executive officer, Boston Scientific Corporation. "In particular, we are pleased with the improvement in both our Interventional Cardiology and Cardiac Rhythm Management divisions. We remain confident in both our strategy and in our outlook for the year."

Keywords for this news article include: Biotechnology Companies, Boston Scientific Corporation.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Biotech Business Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters